Grant: Project Grant - Priority Announcement: Infection and Immunity
Université Laval
$100,000.00
Role of platelets and their mother cell, the megakaryocyte, in COVID-19
EF 2020-21
Résumé
Billions of platelets patrol blood vessels on the ready to prevent the loss of blood when a vessel is injured. The prevention of bleedings is the primarily recognized role of platelets, known since their first description in the late 19th century.
When microbes such as a virus enters the blood circulation, it generates multiple reactions such as fever, loss of blood pressure, alteration of heart rate and respiration. The virus that causes COVID-19 firstly infects the lungs. Megakaryocytes, the cell that makes platelets, are localized in lungs and are thus ideally positioned to interact with the virus. During COVID-19, there is obstruction of blood vessels by blood clot. With their abundance in blood, platelets are chiefly positioned to interact with viruses in blood. Whether megakaryocytes in COVID-19 infected lungs promote inflammation has never been verified. Moreover, how platelets mediate the blood vessel obstructions in COVID-19 is unknown.
Our work has revealed that platelets are activated in COVID-19 patients (Zaid et al. Circulation Research, 2020), which is consistent with accumulating evidence from other laboratories. In this program, we will thus determine how platelets and the cells from which platelets are produced in the lungs, called megakaryocytes, are affected by the virus. We will use very innovative technologies and compelling functional assays that we have developed to study platelets from COVID-19 patients. We will study megakaryocytes in humans and mice, and will uncover how they can modulate the expression of inflammatory molecules in COVID-19. Moreover, the program will permit to understand how antibodies may either protect from, or promote, infection in COVID-19 pathogenesis.
At the end of this project, the team will have identified how platelets modify inflammatory responses in COVID-19 and how manipulating platelets can reduce thrombosis improve health of COVID-19 patients.
Programme
Project Grant - Priority Announcement: Infection and Immunity
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
437464
Name
Boilard Eric
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Cardiovascular System - C: Vascular System
Projecttitle
Role of platelets and their mother cell, the megakaryocyte, in COVID-19
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - Priority Announcement: Infection and Immunity
Keyworddelim
Hemostasis; Inflammation; Megakaryocytes; Platelets; Thrombocytopenia; Thrombosis
Abstract
Billions of platelets patrol blood vessels on the ready to prevent the loss of blood when a vessel is injured. The prevention of bleedings is the primarily recognized role of platelets, known since their first description in the late 19th century.
When microbes such as a virus enters the blood circulation, it generates multiple reactions such as fever, loss of blood pressure, alteration of heart rate and respiration. The virus that causes COVID-19 firstly infects the lungs. Megakaryocytes, the cell that makes platelets, are localized in lungs and are thus ideally positioned to interact with the virus. During COVID-19, there is obstruction of blood vessels by blood clot. With their abundance in blood, platelets are chiefly positioned to interact with viruses in blood. Whether megakaryocytes in COVID-19 infected lungs promote inflammation has never been verified. Moreover, how platelets mediate the blood vessel obstructions in COVID-19 is unknown.
Our work has revealed that platelets are activated in COVID-19 patients (Zaid et al. Circulation Research, 2020), which is consistent with accumulating evidence from other laboratories. In this program, we will thus determine how platelets and the cells from which platelets are produced in the lungs, called megakaryocytes, are affected by the virus. We will use very innovative technologies and compelling functional assays that we have developed to study platelets from COVID-19 patients. We will study megakaryocytes in humans and mice, and will uncover how they can modulate the expression of inflammatory molecules in COVID-19. Moreover, the program will permit to understand how antibodies may either protect from, or promote, infection in COVID-19 pathogenesis.
At the end of this project, the team will have identified how platelets modify inflammatory responses in COVID-19 and how manipulating platelets can reduce thrombosis improve health of COVID-19 patients.
Competitiondate
202010
Approvedterm2
1 yr 0 mth
Pinamesdelim
Boilard, Eric
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~